Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för fgf401. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

9 träffar

Bibliografisk träff 2024-02-13

Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity.

Yang F, Lin Q, Song X, Huang H, Chen X, Tan J, Li Y, Zhou Y, Tu Z, Du H, Zhang ZM, Ortega R, Lin X, Patterson AV, Smaill JB, Chen Y, Lu X.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c01810

Bibliografisk träff 2022-11-17

Targeting Gatekeeper Mutations for Kinase Drug Discovery.

Zhou Y, Xiang S, Yang F, Lu X.

J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.2c01361

Bibliografisk träff 2022-10-24

Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-<i>b</i>]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors.

Yang F, Chen X, Song X, Ortega R, Lin X, Deng W, Guo J, Tu Z, Patterson AV, Smaill JB, Chen Y, Lu X.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.2c01319

Bibliografisk träff 2022-02-04

Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors.

Zhang Z, Li J, Chen H, Huang J, Song X, Tu ZC, Zhang Z, Peng L, Zhou Y, Ding K.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.1c01816

Bibliografisk träff 2021-12-28

Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.

Lu X, Smaill JB, Patterson AV, Ding K.

J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.1c01719

Bibliografisk träff 2021-10-05

Characterization of an aromatic trifluoromethyl ketone as a new warhead for covalently reversible kinase inhibitor design.

Zhang Z, Wang Y, Chen X, Song X, Tu Z, Chen Y, Zhang Z, Ding K.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2021.116457

Bibliografisk träff 2021-03-22

Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.

Deng W, Chen X, Jiang K, Song X, Huang M, Tu ZC, Zhang Z, Lin X, Ortega R, Patterson AV, Smaill JB, Ding K, Chen S, Chen Y, Lu X.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.1c00052

Bibliografisk träff 2020-09-29

Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.

Gampe C, Verma VA.

J Med Chem · review; journal article · DOI 10.1021/acs.jmedchem.0c01177

Bibliografisk träff 2019-04-10

Novel 7-formyl-naphthyridyl-ureas derivatives as potential selective FGFR4 inhibitors: Design, synthesis, and biological activity studies.

Sun C, Fang L, Zhang X, Gao P, Gou S.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2019.04.018